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a b s t r a c t
The efﬁcacy of pEGFP (plasmid expressing enhanced green ﬂuorescent protein)-encapsulated PEGylated
(meaning polyethylene glycol coated) magnesium phosphate nanoparticles (referred to as MgPi-pEGFP
nanoparticles) for the induction of immune responses was investigated in a mouse model. MgPi-pEGFP
nanoparticles induced enhanced serum antibody and antigen-speciﬁc T-lymphocyte responses, as well
as increased IFN-γ and IL-12 levels compared to naked pEGFP when administered via intravenous,
intraperitoneal or intramuscular routes. A signiﬁcant macrophage response, both in size and activity, was
also observed when mice were immunized with the nanoparticle formulation. The response was highly
speciﬁc for the antigen, as the increase in interaction between macrophages and lymphocytes as well as
lymphocyte proliferation took place only when they were re-stimulated with recombinant green
ﬂuorescence protein (rGFP). Thus the nanoparticle formulation elicited both humoral as well as cellular
responses. Cytokine proﬁling revealed the induction of Th-1 type responses. The results suggest DNA-
encapsulated magnesium phosphate (MgPi) nanoparticles may constitute a safer, more stable and cost-
efﬁcient DNA vaccine formulation.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
DNA vaccines are promising vehicles for immunization against
a variety of human pathogens, including HIV [1], Mycobacterium
tuberculosis [2] and malarial parasites [3]. Such immunization with
DNA can elicit both cellular and humoral immune responses [4,5],
and can be administered repeatedly without inducing any anti-
vector immunity. Other beneﬁts of a DNA based vaccine include its
ability to polarize T-cells, especially to a Th1 immunological
response. DNA vaccine formulations are generally more stable
and possess longer shelf-life, which in turn facilitates their
cheaper manufacturing, storage, and shipping compared to that
of protein-based vaccines. Nonetheless, the immunogenicity of
DNA vaccines has been limited by several problems associated
with their delivery, such as poor cellular uptake of DNA, degrada-
tion of the DNA by DNases and lysosomes, and transient DNA
expression. A number of strategies have been used to improve
their potency, including, electroporation, infusion, sonication and
the gene gun [6,7]. Microparticles and nanoparticles that have
been exploited as carriers for such DNAs include polylactidecogly-
colide (PLGA) [8,9], alginate microparticles [10], chitosan nano-
particles [11,12], liposomes [13,14], and virosomes [15]. These
methods are, however, not acceptable in practice because of a
number of crucial limitations, including the requirement for large
amounts of DNA, as well as their low expression levels and
cytotoxicity. As a result, current non-viral genetic vaccine systems
do not efﬁciently activate antigen-presenting cells (APCs) [16], and
so lack the equivalent potency of viral vectors.
It has been suggested that the use of inorganic nanoparticles,
such as phosphates of Ca2þ , Mg2þ , Mn2þ , Ba2þ , Sr2þ , might
eliminate these limitations, yet they remain largely unexplored.
Bulk-precipitated complexes using these ions have been shown to
stimulate varying degrees of DNA transfer efﬁciency across the cell
membrane [17]. Calcium phosphate (CaPi) nanoparticles of aver-
age diameters greater than 400 nm have already been reported to
serve as non-toxic, biocompatible carriers for DNA delivery [18,19]
notwithstanding these particles are too large for efﬁcient intra-
cellular uptake. Our group has previously demonstrated the
potential of ultra low size (o100 nm diameter) CaPi nanoparticles
as efﬁcient vectors for gene delivery in vitro [20–22]. Moreover, in
relation to the induction of immune responses, it has been
observed that smaller particles (o300 nm), when complexed
with DNA, induced better immune responses than did larger
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microparticles (1 mm) [23]; this could be partially attributed to
the ability of smaller particles to be taken up more readily by APCs.
There is also evidence that particle size plays a critical role in the
transfer of nanoparticles in the lymphatic system [24,25]. Our
observations of the greater transfection efﬁciency, in vitro as well
as in vivo, of DNA-encapsulated ultra-low size magnesium phos-
phate nanoparticles [26,27] prompted us to further investigate the
potential of these nanoparticles as DNA vaccine carriers.
Here, we report an investigation of the levels of immunogeni-
city triggered by either a naked pEGFP, or MgPi-pEGFP nanopar-
ticles, via intramuscular (i.m.), intraperitoneal (i.p.) or intravenous
administrations (i.v.) in BALB/c mice. The immune response to the
expressed antigen was studied through a combination of antibody
(IgG) titration, cytokine proﬁle measurement, macrophage (anti-
gen-presenting cell) activation, and lymphocyte proliferation upon
in vitro re-stimulation with recombinant green ﬂuorescence pro-
tein (rGFP). The immune response so induced was markedly
superior to that triggered by either naked pEGFP.
2. Materials and methods
2.1. Materials
All reagents and chemicals were purchased from Sigma unless
otherwise stated. Anti-mouse IgG antibody was obtained from Banga-
lore Genei, India. Interleukin-12 (IL-12) and Interferon-γ (IFN-γ) were
procured from Promega, USA. pEGFP was a gift of Prof. Debi P. Sarcar,
Department of Biochemistry, University of Delhi, India. Recombinant
green ﬂuorescence protein was a gift of Prof. Anirban Maitra, Depart-
ment of Pathology, Johns Hopkins Medical Institute, Baltimore, USA.
2.2. Mice
Inbred strains of pathogen-free female BALB/c mice (6–8 weeks
old; 20–25 g) were obtained from the Animal House Facility,
Department of Zoology, University of Delhi, India. The animals
were reared in uniform hygienic conditions under a controlled
environment (at 20–25 1C and 12 h dark/light cycle) following the
guidelines of the Animal Ethics Committee, University of Delhi,
India. The animal experiments were also executed in strict
accordance to guidelines approved by the Animal Ethics Commit-
tee of the university.
2.3. Preparation of pEGFP-encapsulated MgPi nanoparticles
pEGFP-encapsulated MgPi nanoparticles were prepared using a
water-in-oil microemulsion method exactly as reported in our pre-
vious work [26,27]. Brieﬂy, 25 ml of an AOT (Aerosol OT or sodium bis
(2-ethylhexyl) sulfosuccinate) in hexane solution (0.1 M) was pre-
pared, into which 70 ml of an aqueous solution of magnesium chloride
(1.0 M) and 2.94 mg of pEGFP were dissolved by continuous stirring for
12 h to form microemulsion A. In another 25 ml of AOT in hexane
solution, 70 ml of aqueous solution of (NH4)2HPO4 (1.0 M) and 2.94 mg
of pEGFP, were dissolved by continuous stirring for 12 h to form
microemulsion B. Additional buffer (0.1 M Tris HCl buffer, pH 8) was
added to both microemulsions before stirring so that the aqueous
volume in each microemulsion could reach 450 ml so as to adjust the
Wo (the molar ratio of water to AOT) of each microemulsion to 10.Wo
governs the size of aqueous core in such microemulsion systems and
thus govern the size of the particle formed in these microemulsions.
Both the microemulsions were optically clear solutions after 12 h
stirring. Microemulsion B was then slowly added to microemulsion A
at a rate of 4 ml/h with continuous stirring at 4 1C. The resulting
solution was further stirred for another 12 h. The development of
translucency indicated magnesium phosphate nanoparticle formation
within its aqueous core. Dry ethanol (2 ml) was then added to break
the microemulsion. The mixture was centrifuged for 30 min at 13,000
rpm at 4 1C. The pelleted nanoparticles were washed (4 ) with 15 ml
n-hexane and the particles dispersed in PBS (pH 7.2) by vortexing. The
dispersed nanoparticles were dialyzed for 12 h in a 12 kD cut-off
dialysis membrane bag to yield a clear dispersion. The dispersed
nanoparticles were characterized by particle size determination. The
void (placebo) nanoparticles were also prepared using exactly the
same protocol without adding pEGFP solution.
2.4. Tagging of methoxy-PEGamine to pEGFP-encapsulated MgPi
nanoparticles
In order to render the pEGFP-encapsulated MgPi nanoparticles
long circulating inside the body upon their administration via the
different routes, their surfaces were modiﬁed to acquire polyethylene
glycol (PEG) terminals. This process is referred to as "PEGylation" of
the surface. To obtain PEGylated nanoparticles, both void as well as
pEGFP-encapsulated MgPi nanoparticles were ﬁrst coated with the
highly adhesive polymer, polyacrylic acid (PAA). Acid-coated MgPi
nanoparticles were then conjugated with methoxy PEG-amine (Mol
Wt 5000) to create the PEGylated nanoparticles. Brieﬂy, a 10 ml
dispersion of MgPi nanoparticles in PBS (pH 7.4) obtained from the
above process was incubated with 10 ml of acid neutralized (pH 8) PAA
(5 kD, 0.5% V/V) for 2–3 h with stirring, followed by a dialysis (12 kD
membrane) to remove excess polymer. The carboxylate groups of PAA
were conjugated to amine groups of methoxy PEG-amine using EDCI
(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride).
Methoxy PEG-amine (50 ml of 40 mg/ml) was added to the nanopar-
ticle suspension with continuous stirring and to this, 50 ml of EDCI (20
mg/ml) was added. Stirring was continued for 8 h, followed by 2–3 h
of dialysis to remove all the unconjugated molecules. The particle size
of these PEGylated nanoparticles was again measured by DLS to
reconﬁrm whether the PEGylation process had caused any change in
the nanoparticles sizes. Lyophilized product was stored at 4 1C until
further use. The PEGylated nanoparticle formulation was readily
dispersible in an appropriate injectable volume of PBS (pH 7.4). We
refer pEGFP-encapsulated PEGylated MgPi nanoparticles to as MgPi-
pEGFP nanoparticles in this study.
2.5. Determination of the size of the nanoparticles
The particle sizes of both the void as well as the pEGFP-
encapsulated nanoparticles in water-in-oil microemulsions as well as
in aqueous solutions were determined by a dynamic light scattering
(DLS) technique. Brieﬂy, the measurements were done with a Broo-
khaven BI8000 instrument ﬁtted with a BI200SM goniometer. An
argon-ion air-cooled laser was operated at 488 nm as the light source
and the intensity of scattered light were recorded on a scattering angle
of 901. The time-dependent autocorrelation function was derived
using a 136-channel digital photon correlator. The particle size was
calculated from the auto correlation function using the Stokes–Einstein
equation: d ¼ kt/3πηD, where D is the translational diffusion
coefﬁcient, d is the particle diameter, η is the viscosity of the liquid
in which particles are suspended, k is Boltzmann’s constant and T is
absolute temperature.
2.6. Entrapment efﬁciency (E%)
The pEGFP-encapsulated nanoparticles in AOT microemulsion
were separated after ultracentrifugation (40,000 rpm for 4 h at 4
1C) and the pellet, after washing with hexane, was dissolved in
acidic buffer (pH 3). The amount of DNA released from the
nanoparticles, [DNA]r, was estimated spectrophotometrically by
measuring the optical density at λ260nm. The entrapment efﬁciency
(E) was then calculated from the amount of DNA originally added
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to the microemulsion ([DNA]0) using the equation E% ¼ [DNA]r
/[DNA]0100.
2.7. Agarose gel electrophoresis of free, encapsulated, and adsorbed
pEGFP
Agarose gels were used for electrophoresis. In order to demonstrate
the encapsulation of pEGFP inside particles and its protection from
external DNase, MgPi-pEGFP nanoparticles were run onto agarose gels
(1%). Brieﬂy, 10 ml of an aqueous dispersion of MgPi-pEGFP nanopar-
ticles (5 mg/100 ml) solutionwas incubated with 5 ml of DNase1 (5 mg/
ml in Tris buffer) for 15–20min at 4–8 1C andwas ﬁnally loaded onto a
gel. As a control, the same volume of untreated nanoparticles contain-
ing the same amount of pEGFP was also loaded onto the gel. Naked
pEGFP (2 ml of 0.5 mg/ml) was either loaded fresh or after incubation
with placebo MgPi for adsorption onto particle surfaces overnight at
4–8 1C. In both cases, control experiments involving treatment with
DNase1 for 30 min prior to loading were also conducted.
2.8. In vivo gene expression
Two groups of young BALB/c mice (n¼6) were injected with
either 1.8 mg of naked pEGFP or 1.8 mg of pEGFP delivered via
nanoparticle formulation. Both groups of mice were injected
intraperitoneally. Seven days post-injection, mice were sacriﬁced
and their lungs, livers, spleens and lymph nodes were harvested
under aseptic conditions. The tissue extracts were prepared in PBS
by homogenization and centrifugation (12,000 rpm/4 1C). The
tissue homogenates were assayed for total protein using Lowry’s
method. Each tissue was normalized for protein and assayed for
the expressed green ﬂuorescence protein (GFP) using ﬂuorimeter
(excitation ﬁlter 365 nm and emission ﬁlter 510 nm). The back-
ground ﬂuorescence (RFU) obtained from the tissue homogenates
of untreated mice was subtracted from the RFU obtained from
each of the tissue homogenates of pEGFP treated mice.
2.9. Immunization
BALB/c mice were immunized three times each with the MgPi-
pEGFP nanoparticle as well as with control particles and naked pEGFP
at weeks 0, 2 and 4. Immunizations were carried out via three routes –
intravenous, intraperitoneal or intramuscular. A total of 36 animals
were immunized (12 animals per route; 6 with naked pEGFP and
6 with MgPi-pEGFP nanoparticles). The nanoparticle formulations
(MgPi-pEGFP) were dispersed in phosphate buffer saline (pH 7.4)
and injected (100 ml containing 0.6 mg pEGFP) into each mouse (total
dose of 1.8 mg of pEGFP/animal with three injections at weeks 0, 2 and
4). Equivalent amounts of naked pEGFP were also injected in similar
ways into animals as positive controls. A group of 6 mice were also
injected in a similar way with void PEGylated MgPi nanoparticles to
study the effect of nanoparticles themselves on mice.
2.10. Sera and tissue collection
Mice were bled through the retro-orbital plexus and the sera
separated by centrifugation for immunoglobulin assessment. The
liver, lung, thymus and spleen of these animals were carefully
dissected out and then washed in sterile PBS for further studies.
2.11. Antibody assays
Serum anti-GFP antibody (IgG) titers were measured by ELISA
using green ﬂuorescence protein (GFP) as the solid phase antigen.
Brieﬂy, ELISA plates (96-well U bottom, Tarson, India) were coated
with recombinant GFP overnight (200 ml of 5 mg/ml) and non-
speciﬁc sites blocked with 5% bovine serum albumin in PBS. After
washing twice with PBS/0.5% Tween-20, 100 μl of serum samples
diluted in PBS were added to the wells. After overnight incubation
at 4 1C, the plates were successively washed with Tween-20/PBS
and incubated with 1:2000 dilutions of alkaline HRP-conjugated
goat anti-mouse IgG antibodies(100 μl) for 2 h at room tempera-
ture. Plates were washed again and orthophenylenediamine dihy-
drochloride (OPD) in 0.05 M citrate buffer (pH 5.0, 100 ml of 1 mg/
ml) and 2 ml 30% H2O2 were added. Absorbance at 490 nm was
recorded after the addition of oxalic acid (10 ml) as stop solution.
2.12. Macrophage (antigen presenting cells) activation
Splenocytes, consisting of both macrophages and lymphocytes,
were prepared from all the experimental mice using the standard
protocol. Brieﬂy, the spleens were dissected out and minced in PBS on
a stainless steel mesh ( 4 mm) to make single cell suspensions and
then, upon centrifugation, the cells were collected and resuspended in
complete RPMI media containing antibiotics (streptomycin and peni-
cillin). The collected cells were then used to analyze the changes in the
number of macrophages and their activations after the differing
immunization protocols. For determining the change in the number
of macrophages in spleens, 1107 splenocytes were plated into 100
mm culture plates in complete RPMI and incubated at 37 1C. After 2 h
of incubation, non-adherent cells were washed 3 times with PBS and
the adherent cells (about 98% cells were macrophages based both on
their morphology and non-speciﬁc esterase staining) were detached
and counted using hemocytometer. To measure the difference in the
activation of macrophages with differing immunization routes, we
incubated the 1106 splenocytes with or with rGFP for 24 h at 37 1C
in a CO2 incubator. After 24 h, the non-adherent cells were washed
and the adherent macrophages were analyzed for change in morphol-
ogy and phagocytic activity.
2.13. Lymphocyte proliferation assay
Lymphocyte proliferation of the immunized mice was carried out
using MTT colorimetric assay as previously described [28]. Splenic
lymphocytes were prepared from all experimental mice using the
standard protocol. Brieﬂy, the spleens were dissected out and minced
in PBS on a stainless steel mesh (4 mm) to make a single cell
suspension. The erythrocytes were lysed by 0.54% NH4Cl (pH 7.4).
After centrifugation, the cells were re-suspended in complete RPMI
media supplemented with antibiotics (streptomycin and penicillin)
and 1  106 cells were seeded into eachwell of 96-well culture plates.
rGFP (5 μg/ml) was used as a speciﬁc stimulating antigen. Wells
without stimulating antigenwere used as negative control. All the cells
were cultured at 5% CO2 and 37 1C for 72 h. Two hour prior to
termination, 20 ml MTT (5 mg/ml) was added into each well. After the
appearance of purple formazan crystal, the culture plate was centri-
fuged. The supernatant was removed and the crystals solubilized in
100 ml of dimethyl sulphoxide (DMSO) and the absorbance measured
at 570 nm to determine the stimulation index. All experiments were
done in triplicate and repeated twice with 3 animals each.
2.14. Assays for IFN-γ and IL-12
Splenocytes prepared from mice were seeded into 96-well culture
plates (1106 cells/well) in complete RPMI media supplemented with
antibiotics. The splenocytes were cultured in the presence of rGFP for
24 h. The culture medium was collected and assayed for the presence
of IFN-γ and IL-12 by Sandwich ELISA, as per the protocol provided for
each cytokine by BD Pharmingen (CA, USA).
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2.15. Statistical analysis
The statistical signiﬁcance of the different data points between
naked pEGFP treated and MgPi-pEGFP nanoparticles treated
mouse groups was determined using One-way ANOVA with Tukey
post-hoc testing. This analysis was performed with SPSS software
(version 13.0, SPSS Inc., Chicago, IL). In all cases, values represent
mean 7 S.D. (n ¼ 6) and differences were considered signiﬁcant
at p o 0.05.
3. Results
3.1. Preparation and characterization of the nanoparticles
Void and pEGFP-encapsulated MgPi nanoparticles were formed
in the aqueous core of the AOT/hexane microemulsion. The
strategy involved the precipitation of the phosphate salts of
magnesium in the absence or presence of pEGFP to obtain void
or pEGFP-encapsulated MgPi nanoparticles respectively. The nano-
particle pellet obtained upon centrifugation of the microemulsion
was easily dispersible in aqueous solution. The calculated loading/
encapsulation efﬁciency (E%) as deﬁned earlier was found to be
nearly 99%. The mean size distributions of the MgPi-pEGFP
nanoparticles was in the range of 30–50 nm in water-in-oil
microemulsion and 110–130 nm in aqueous dispersion. The
increase in sizes of nanoparticles in aqueous solution can be
attributed to the slight aggregation of nanoparticles in aqueous
media. A representative size distribution proﬁle of MgPi-pEGFP
nanoparticles is shown in Fig. 1. No differences between the sizes
of the void and pEGFP-encapsulated MgPi nanoparticles were
observed, indicating that DNA incorporation does not lead to an
increase in particle size. These observations are also corroborated
by our previous publication [26], so conﬁrming the reproducibility
of our fabrication and characterization methods. The PEGylation
process did not contribute to any change in the particle sizes of
void and pEGFP-encapsulated MgPi nanoparticles either (data not
shown).
3.2. Intracellular protection of pEGFP by nanoparticle matrices
To test whether the MgPi nanoparticles could protect encapsu-
lated pEGFP from nuclease digestion, MgPi particles with encap-
sulated pEGFP were subjected to extensive DNase treatment
before undergoing gel electrophoresis (Fig. 2). It was found that
while naked pEGFP migrated to its usual position (lane 2), pEGFP
encapsulated inside the nanoparticles remained at the top, and
hardly entered into the gel (lane 4). Although DNase 1 completely
digested the naked pEGFP, as demonstrated in lane 3, the pEGFP in
MgPi nanoparticles was totally protected, as seen in lane 5.
However, when the pEGFP was adsorbed only onto the surface
of void nanoparticles, it migrated under the applied current almost
like naked pEGFP (lane 6), becoming completely degraded by
DNase as seen in lane 7. This was expected, as nanoparticle
surfaces clearly do not offer enough protection in and of them-
selves. These results clearly demonstrate that DNA that is com-
pletely encapsulated within the rigid matrix of the magnesium
phosphate nanoparticles is offered signiﬁcant protection. This
result conﬁrms our previous results, obtained both with this
nanoparticle [26] as well as with CaPi nanoparticles [21,22].
3.3. In vivo green ﬂuorescence protein (GFP) expression
To test the utility of MgPi nanoparticle-mediated gene delivery
in vivo, both generally and to speciﬁc organs in particular,
immature BALB/c mice were injected with MgPi-pEGFP
nanoparticles and the expression of green ﬂuorescence protein
within different body tissues measured (Fig. 3). GFP expression
was observed in all the major tissues of the body, but especially in
the immunologically-key spleen and lymph nodes. The level of
GFP expression for all tissues examined was greater for
nanoparticle-mediated delivery than after naked pEGFP adminis-
tration, probably due to the protection from DNase degradation.
Interestingly, the nanoparticle-mediated GFP expression was sig-
niﬁcantly higher (p o 0.05) in spleen, lungs, and lymph nodes.
The highest GFP expression was observed in liver.
3.4. Enhanced antibody response to pEGFP delivered via MgPi-pEGFP
nanoparticles
Enhanced green ﬂuorescent protein (EGFP) is a marker gene
and it has been previously reported to have immunogenic poten-
tial [29,30] with an advantage of being traced via multiple
techniques. Thus in order to evaluate the efﬁcacy of MgPi as a
Fig. 1. Representative particle size distribution or dynamic light scattering of MgPi-
pEGFP nanoparticles in (A) water-in-oil microemulsion and (B) aqueous buffer.
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novel carrier for delivery of DNA vaccine we opted to use pEGFP.
The MgPi-pEGFP nanoparticles induced signiﬁcant antibody
responses in BALB/c mice when they were immunized either
intravenously, intraperitoneally or intramuscularly (Fig. 4). Mice
immunized i.p and i.v. produced higher titers of anti-GFP IgG than
those immunized i.m. The MgPi-pEGFP nanoparticles yielded a
1000–5000-fold increase in the antibody titers in the case of
intravenous immunization, and only a 100–500-fold in the case of
intraperitoneal immunization. But, there was little increase
between antibody titers of MgPi-pEGFP nanoparticles and naked
pEGFP when injected into muscle.
3.5. Macrophage activation
Antigen presenting cells play a pivotal role in induction of
immune response. Since uptake of vaccine and presentation of
expressed protein is key to the success of immunization. We next
examined changes in macrophage activity after immunization
with the MgPi-pEGFP nanoparticles, naked pEGFP and void MgPi
vectors. There was an increase in the overall number of macro-
phages (APCs) in spleens of mice immunized with the MgPi-pEGFP
vector, compared to those after immunization with naked pEGFP
or those in the unimmunized (control with void PEGylated MgPi)
mice (Fig. 5A). Immunization via i.v. and i.p. administration was
more efﬁcient than via i.m. administration. Upon i.v. administra-
tion, the nanoparticles induced signiﬁcantly more macrophages (p
o 0.05) than the naked pEGFP or control treatments. Upon i.p.
administration, the nanoparticles induced signiﬁcantly more
macrophages (p o 0.05) than that only of the control group. As
shown in Fig. 5B the macrophage obtained from mice immunized
with MgPi-pEGFP via i.v. route were much enlarged in its size, a
hallmark of their activation. Additionally, we also observed
increased phagocytic activity in macrophage from MgPi-pEGFP
immunized mice compared to those from immunized with naked
pEGFP or control mice.
Fig. 2. Photomicrograph of agarose (1%) gels revealing free, encapsulated and
adsorbed pEGFP. Lane 1: after digestion with HindIII enzyme. Lane 2: Free pEGFP.
Lane 3: pEGFP treated with DNase I. Lane 4: MgPi-pEGFP nanoparticles. Lane 5:
MgPi-pEGFP nanoparticles treated with DNase I. Lane 6: pEGFP adsorbed on void
magnesium phosphate nanoparticles. Lane 7: pEGFP adsorbed on void magnesium
phosphate nanoparticles and then treated with DNaseI.
Fig. 3. Expression of green ﬂuorescence protein (GFP) in various body tissues.
Seven days after intraperitoneal administration of MgPi-pEGFP nanoparticles
encapsulating 1.8 mg pEGFP in mice, various body tissues were excised and
processed to estimate the amount of GFP expressed. Values represent mean 7 S.
D. (n ¼ 6). *P o 0.05, signiﬁcantly different when compared to naked pEGFP.
Fig. 4. Serum GFP-speciﬁc total IgG titer following intravenous, intraperitoneal or
intramuscular administration of naked pEGFP and MgPi-pEGFP nanoparticles.
Values represent mean 7 S.D. (n ¼ 6). *P o 0.05, signiﬁcantly different when
compared to naked pEGFP.
Fig. 5. (A) Macrophages (%) in the splenocytes obtained from harvested spleens of
control, naked pEGFP or MgPi-pEGFP administered mice. Values represent mean 7
S.D. (n ¼ 6). *P o 0.05, signiﬁcantly different when compared to naked pEGFP as
well as control. (B) Photomicrograph for macrophage activation. Macrophages were
obtained from the spleen of control and pEGFP (naked or MgPi-encapsulated) i.v.
immunized mice and co-cultured with lymphocytes from the same mice in
presence of rGFP. Arrows indicating phagocytosis of dead cells (200 magniﬁca-
tion, Nikon 100 microscope).
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3.6. Lymphocyte proliferation
To check the speciﬁcity of the immune response generated in
the mice, we re-stimulated the lymphocytes collected from
immunized mice with rGFP in vitro and looked for increases in
their proliferation. Fig. 6 reveals a signiﬁcantly (p o 0.05)
enhanced proliferation of splenic lymphocytes obtained from mice
immunized with MgPi-pEGFP vector upon re-stimulation with
rGFP as compared to those obtained from mice immunized with
naked pEGFP or from unimmunized control mice. Immunization
with MgPi-pEGFP nanoparticles led to greater lymphocyte prolif-
eration via all routes of immunization, albeit not so pronounced as
in the case of the i.m. route.
3.7. Cytokine production
The production of the cytokines IFN-γ and IL-1 by in vitro
splenocytes isolated from immunized mice that had been re-
stimulated with recombinant green ﬂuorescence protein (rGFP)
antigen are shown in Fig. 7. The nanoparticles delivered i.v. and i.p.
triggered signiﬁcantly (p o 0.05) more IFN-γ and IL-12 than
immunization with naked pEGFP or the control mice. However, no
appreciable production of either of these cytokines was observed
when the nanoparticles were delivered i.m. However, when
administered i.m., the naked pEGFP resulted in more cytokines
than the nanoparticles.
4. Discussion
This study serves to demonstrate that inorganic phosphate
nanoparticles such as magnesium phosphate can serve not only as
an efﬁcient DNA delivery system, but also act as potent adjuvants
for the induction of effective DNA vaccine immune responses.
Although an array of microparticles and nanoparticles have shown
potential as pDNA delivery systems for the boosting of immune
responses, MgPi nanoparticles appear to offer signiﬁcant advan-
tages from the point of view of both efﬁcacy and toxicity. In a
previous study, we have shown these nanoparticles demonstrate
high transfection efﬁciency [26], and did not show any cytotoxicity
in cell culture assays [27]. They triggered no observable adverse
effects when injected into mice. As an important constituent of
viable bone substitutes, as well as an important and normal
normal tissue constituent in vivo [31,32], magnesium hydroxya-
patite has long been shown to be biocompatible, and is regarded
as very safe for human use. Magnesium phosphate is also in the
FDA’s GRAS list [33].
Due to the low transfection rates elicited by other particulate
carriers, high doses of DNA have usually been required to trigger
sufﬁcient immunization. Effective induction of robust T-cell
responses are generally only achieved with a minimum of 50–
200 mg doses of DNA [34,35], as seen in the recent study by Meerak
et al., wherein they immunized Balb/c mice with 50 mg DNA
together with chitosan nanoparticles [35]. However here, in the
case of magnesium phosphate nanoparticles, the total effective
doses of DNA administered to animals were as small as 1–2 mg,
most probably due to the very high transfection efﬁciency, which
was comparable to that of Polyfects [26].
This study also provides several other improvements and
advantages for genetic immunization: the MgPi-pEGFP nanopar-
ticles are smaller in size than particles used in previous studies,
which were either larger than 300 nm [35] or in the micron range
[23]. The average diameter of the nanoparticles in this study was
considerably less than 150 nm, and was thus ideal for engaging the
clathrin-coated pit pathway for entry into the cytosol and endo-
somal compartments [36–44].
These nanoparticles were also able to provide a very high level
of protection for DNA from degradation (Fig. 2), which is crucial for
efﬁcacious genetic therapy. Naked DNA is highly prone to extra-
cellular and intracellular nuclease attack, a major challenge for
efﬁcient DNA transfection both in vitro and in vivo. Lechardeur
et al. [45] showed that naked DNA microinjected into the cyto-
plasm of HeLa and COS-cells is degraded by cytosolic nucleases.
Fig. 6. Analysis of cell proliferation upon re-challenge with recombinant GFP of
lymphocytes obtained from control, naked pEGFP or MgPi-pEGFP administered
mice. Values represent mean 7 S.D. (n ¼ 6). *P o 0.05, signiﬁcantly different
when compared to naked pEGFP.
Fig. 7. In vitro release of (A) IFN-γ and (B) IL-12 by stimulated splenocytes.
Splenocytes isolated from experimental animals (control, pEGFP, or MgPi-pEGFP
injected) were stimulated with recombinant green ﬂuorescence protein (rGFP)
antigen for 24 h. Culture supernatants were collected and assayed for presence of
(A) IFN-γ and (B) IL-12 using sandwich ELISA kit from BD Pharmingen, USA. Values
represent mean 7 S.D. (n ¼ 6). *P o 0.05, signiﬁcantly different when compared
to naked pEGFP as well as control.
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Co-injected TRITC-dextran spread throughout the cytosol, but
naked plasmid DNA progressively disappeared from the cytoplasm
with a half life of 90 min. They concluded that protection of DNA
from endonucleases, either by complexing or encapsulating it was
necessary. However all subsequent vectors have been able to offer
only partial in vivo protection.
EGFP is a commonly used reporter protein used in diverse array of
scientiﬁc disciplines, for its ease of detection. In addition, previous
studies have identiﬁed an immunodominant H2-Kd restricted CTL
epitope present withing EGFP protein recognized by Balb/c mice,
making it a suitable candidate for evaluation of vaccine- induced
immune response [29]. Thus in order evaluate the efﬁcacy of Mg-Pi
nanoparticles as an optimal carrier for DNA vaccine we preferred
pEGFP. In our previous study we have reported that MgPi nanoparti-
cles shows comparable or may be better transfection efﬁciency in
MCF-7, U87, Hela, COS-7 cells than the commonly used PolyFect
reagent [26,27]. And it also has the advantage of being highly
biocompatible and non-toxic.
The surfaces of the MgPi nanoparticles can be easily modiﬁed
for prolonged DNA retention and circulation, and thus expression.
The GFP expression in the various harvested tissues clearly
demonstrated that DNA encapsulated in MgPi nanoparticles could
efﬁciently traverse all paths to reach their respective cellular sites
without degradation. The small size of the particles also facilitated
their efﬁcient uptake by macrophages, as demonstrated both by
the increased expression of GFP in the spleen, as well as the
increase in the number of macrophages in the spleens of mice
immunized with MgPi-pEGFP (Fig. 3). However, the high GFP
expression in liver could be due to the fact that a large proportion
of the particles, as well as the pEGFP, was taken up by liver via
parenchymal cells rather than macrophages [34].
MgPi nanoparticles are also clearly capable of inducing potent
adjuvant effects for antibody induction against encoded protein, so
facilitating protection against pathogen challenge. The antibody
response triggered by the encapsulated pEGFP is many fold-higher
than for naked pEGFP, especially when administered via i.v and i.p
routes. The modest cellular and humoral immune response trig-
gered by intramuscularly injected DNA has also been remarked on
previously [46]. Cherif et al. [47] studied the immunogenicity of
novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine
using different routes of administration and they also highlighted
that the better protection was observed in the following order: i.p.
4 i.v. 4 s.c. Various studies, using the same formulation, have
demonstrated that route of injection inﬂuenced the immune
response. However, in the larger number of studies that have
evaluated DNA-based immunization, only few have directly com-
pared the immune responses generated by different routes of
delivery. Although the mechanism is not clearly understood, we
hypothesize that the better response in case of i.p. and i.v. over i.m.
immunization with MgPi-pEGFP could be because, for these
routes, there is comparatively greater opportunity for the macro-
phages to ingest the MgPi-pEGFP particles. It might also be
because of the poor distribution, inefﬁcient expression or rapid
degradation of intramuscularly injected DNA [48].
The MgPi-pEGFP nanoparticles might also be activating macro-
phages or antigen presenting cells (APCs) upon immunization via the i.
v. and i.p. routes. The poor macrophage response in the case of the
intramuscular route might be due to the poor uptake of the nano-
particle formulation by the macrophages in this tissue. Further, the
enhanced lymphocyte proliferation seen upon re-challenge with rGFP
corroborates the idea that the response generated is speciﬁc against
the antigen expressed by the pEGFP. Increases in lymphocyte prolif-
eration and enhanced APC activity take place only when they are re-
stimulated with speciﬁc antigen, such as the rGFP here. The enhanced
cellular response is also documented in the cytokine proﬁles, which
indicated a better induction of Th-1 type responses.
5. Conclusions
The MgPi-pEGFP vaccine is expressed in all the major tissues of
the body, but especially in the immunologically relevant spleen
and thymus. It elicit both humoral (as conﬁrmed by increases in
antibody titer), as well as cell-mediated responses (as demon-
strated by lymphocyte proliferation). The cytokine study suggests
a better induction of Th-1 type responses upon nanoparticle-
mediated delivery of DNA, and the increased lymphocyte prolif-
eration upon re-challenge with antigen conﬁrmed the speciﬁcity
of the response. Intravenous and intraperitoneal routes of admin-
istration were superior to intramuscular routes, as indicated by
immunoglobulin assays, lymphocyte proliferation and APC activa-
tion studies. Thus, magnesium phosphate nanoparticles show
great promise as efﬁcient carriers for DNA, as well as for effective
immunization with encoded protein.
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